🇺🇸 FDA
Patent

US 9126994

Crystalline form of a quinolinone-carboxamide compound

granted A61KA61K31/46A61P

Quick answer

US patent 9126994 (Crystalline form of a quinolinone-carboxamide compound) held by Theravance Biopharma R&D IP, LLC expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K31/46, A61P, A61P1/00, A61P1/04